Archive: 01/11/2017
TAVR cost-effective compared with SAVR in intermediate risk patients with aortic stenosis
Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate ...
Nov 1, 2017
Results from the ABSORB IV trial reported
Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS) trial to date, found BVS to be noninferior to a cobalt-chromium everolimus-eluting stent (CoCr-EES) for target ...
Nov 1, 2017